A Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Therapy in U.S. Military Veterans with Chronic PTSD Timeline

Participant Enrolled in Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Therapy in U.S. Military Veterans with Chronic PTSD

April 15, 2022
First Participant Treated in A Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Therapy in U.S. Military Veterans with Chronic PTSD

February 3, 2022
First Participant Will Enroll in A Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Therapy in U.S. Military Veterans with Chronic PTSD

January 24, 2022
First Participant Screening in A Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Therapy in U.S. Military Veterans with Chronic PTSD

December 15, 2021
First Participant Consented to Participation in A Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Psychotherapy in U.S. Military Veterans with Chronic PTSD

November 23, 2021
Site Initiation Visit Takes Place for Phase 2 Study at the Veterans Affairs Medical Center in Bronx, New York

September 22, 2021
Phase 2 Study at the Bronx, New York Veterans Affairs Medical Center

February 25, 2021
A Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Therapy in U.S. Military Veterans with Chronic PTSD

October 19, 2020